[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366965-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366965-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ai-guided-sers-defines-a-pan-cancer-diagnostic-biomarker-research-article","AI-Guided SERS Defines a Pan-Cancer Diagnostic Biomarker - Research Article","","AI-Guided SERS advances noninvasive multi-cancer detection by combining an automated exosome capture SERS chip with AI-enabled molecular fingerprinting. The peptide-functionalized chip selectively enriches exosomes from patient serum to enhance label-free Raman signals. Spectral analysis distinguishes cancer from healthy samples with 97.4% accuracy, achieves 97.08% for early-stage detection, and reaches 93.89% accuracy for classifying ten common cancer types including breast, thyroid, esophageal, kidney, pancreatic, duodenal, lung, colorectal, ovarian, and gastric cancers. Molecular profiling identifies exosomal deoxyadenosine triphosphate as a pan-cancer biomarker consistently upregulated across diverse tumors, supporting fully automated, scalable clinical translation for early and differential diagnosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ai-guided-sers-defines-a-pan-cancer-diagnostic-biomarker-research-article/366965/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ai-guided-sers-defines-a-pan-cancer-diagnostic-biomarker-research-article/366965.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the AI-guided SERS system detect multiple cancers from a single serum test?","Question",{"text":63,"@type":64},"It uses a peptide-functionalized SERS chip to selectively enrich exosomes from patient serum, then applies AI-driven spectral analysis of Raman fingerprints to distinguish cancer types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What diagnostic performance is reported for cancer detection and classification?",{"text":68,"@type":64},"The system reports 97.4% accuracy for distinguishing cancer from healthy samples, 97.08% accuracy for early-stage cancer detection, and 93.89% accuracy for classifying ten common cancer types.",{"name":70,"@type":61,"acceptedAnswer":71},"What pan-cancer biomarker was identified and how was it supported?",{"text":72,"@type":64},"Exosomal deoxyadenosine triphosphate is identified as a promising pan-cancer biomarker, consistently upregulated across diverse tumor types based on molecular profiling.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366965,1790293756,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nAI-Guided SERS Deﬁnes a Pan-Cancer Diagnostic Biomarker  \nCai Zhang, Wen-Hui Zhao, Duo Zuo, Tianxing Zhou, Wenjing Hou, Lingwei Wang, Shangheng Shi, Yang Yang, Yuanyuan Liu, Shao-Kai Sun, Li Ren, Zhaoxiang Ye, Dingbin Liu, Dong Li,* Xiaoyuan Chen,* and Jihui Hao*  \nEarly and accurate detection of multiple cancers through a single test remains an unmet clinical need, hindered by current limitations in accuracy, throughput, automation, and multiplexing. Here, we present an AI-powered SERS chip that combines automated exosome capture with AI-enabled molecular ﬁngerprinting to accurately distinguish ten common cancer types from a single serum test. The system employs a peptide-functionalized SERS chip enabling the selective enrichment of exosomes directly from patient serum, enhancing label-free Raman ﬁngerprint signals. AI-driven spectral analysis achieved 97.4% accuracy in distinguishing cancer from healthy samples, 97.08% accuracy for early-stage cancer detection, and 93.89% accuracy in classifying ten common cancer types, including breast, thyroid, esophageal, kidney, pancreatic, duodenal, lung, colorectal, ovarian, and gastric cancers. Crucially, based on molecular proﬁling, we identiﬁed exosomal deoxyadenosine triphosphate as a promising pan-cancer biomarker consistently upregulated across diverse tumor types. This discovery establishes a potential pan-cancer diagnostic marker, while the fully automated, scalable platform oﬀers signiﬁcant promise for clinical translation in early and diﬀerential cancer diagnosis.  \n1. Introduction  \nCancer remains a leading cause of mortality worldwide, and early detection is key to improving survival outcomes. [1] Noninvasive liquid biopsy oﬀers signiﬁcant advantages, including minimal invasiveness, high reproducibility, convenience, and the capacity for real-time dynamic monitoring, making it a promising approach for early cancer detection and screening. Current liquid biopsy tests primarily rely on broadspectrum serum tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), as well as cancer-speciﬁc markers. [2,3] However, these markers suﬀer from limited speciﬁcity and high false-positive rates, which restrict their diagnostic accuracy, particularly their inability to diﬀerentiate multiple cancer types in a single test. [4] Although emerging biomarkers including circulating tumor DNA,[5] microRNAs,[6] and circulating tumor cells[7] show potential for cancer diagnosis, challenges related to sensitivity,  \nC. Zhang, L. Wang, Y. Yang, Y. Liu, Z. Ye, D. Liu Department of Radiology  \nTianjin Medical University Cancer Institute and Hospital National Clinical Research Centre of Cancer  \nTianjin’s Clinical Research Center for Cancer Tianjin Key Laboratory of Digestive Cancer Hexi District, Tianjin 300060, China  \nW.-H. Zhao, D. Li  \nDepartment of Radiology  \nTianjin Medical University General Hospital Heping District, Tianjin 300052, China  \nE-mail: [dr_lidong@tmu.edu.cn](dr_lidong@tmu.edu.cn)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202516268](https://doi.org/10.1002/advs.202516268)[ ](https://doi.org/10.1002/advs.202516268)© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202516268  \nD. Zuo, L. Ren  \nDepartment of Clinical Laboratory  \nTianjin Medical University Cancer Institute and Hospital Hexi District, Tianjin 300060, China  \nT. Zhou, S. Shi, J. Hao  \nDepartment of Pancreatic Cancer  \nTianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin’s Clinical Research Center for","cbCaik2l2AKi2Rtf","https://ap.wps.com/l/cbCaik2l2AKi2Rtf","pdf",6436383,13,"English","# Introduction\n# Liquid biopsy and limitations\n# Exosomes and Raman/SERS rationale\n# Automated AI-enabled diagnostic approach\n# Pan-cancer biomarker discovery\n# Clinical translation potential","[{\"question\":\"How does the AI-guided SERS system detect multiple cancers from a single serum test?\",\"answer\":\"It uses a peptide-functionalized SERS chip to selectively enrich exosomes from patient serum, then applies AI-driven spectral analysis of Raman fingerprints to distinguish cancer types.\"},{\"question\":\"What diagnostic performance is reported for cancer detection and classification?\",\"answer\":\"The system reports 97.4% accuracy for distinguishing cancer from healthy samples, 97.08% accuracy for early-stage cancer detection, and 93.89% accuracy for classifying ten common cancer types.\"},{\"question\":\"What pan-cancer biomarker was identified and how was it supported?\",\"answer\":\"Exosomal deoxyadenosine triphosphate is identified as a promising pan-cancer biomarker, consistently upregulated across diverse tumor types based on molecular profiling.\"}]","AI-Guided SERS Defines a Pan-Cancer Diagnostic Biomarker - Research Article | PDF",1790168474,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62b0022455cb1d2ead1bc2d6a23b91a1.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/450e4bcb2fd8a7d26f8b8e881e4777a8.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44d6fc118a91a896ad8f7471892a3d45.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80a08e8075b26185ffd4c7cbcdc4814f.webp",980,1287]